Endo get preliminary injunction against QuVa Pharma over vasopressin product

Ireland-headquartered Endo International (Nasdaq: ENDP), along with its subsidiaries Par Pharmaceutical and Par Sterile Products, have obtained a preliminary injunction preventing QuVa Pharma from marketing and releasing its planned vasopressin product that would compete with Par's Vasostrict, the first and only vasopressin injection, USP, product approved by the US Food and Drug Administration.

The preliminary injunction, issued by Brian Martinotti, US District Judge, is effective through the conclusion of a trial, which has not yet been scheduled.

In August 2017, Par filed a complaint against Texas, USA-based QuVa and several individual defendants in the US District Court for the District of New Jersey (Case No. 17-6115) alleging, among other claims, the misappropriation of Par's trade secrets by the defendants in connection with QuVa's development of a bulk compounded vasopressin product.